Expert consensus on the long-term use of lanadelumab in hereditary angioedema: Toward harmonized care
{{output}}
Background: Hereditary angioedema (HAE) is a rare, potentially life-threatening disease caused in most cases by C1 inhibitor deficiency. Lanadelumab, a monoclonal antibody targeting plasma kallikrein, is an effective long-term pr... ...
